Explore Our Network

Advanced Light Devices manufactures the patent pending Hemealumen Polychromatic Device Innovative Solutions for Treating Infectious and Neurodegenerative Diseases Company Overview Advanced Light Devices is a pioneering company established in the early 2000s, dedicated to developing advanced medical technologies for the treatment of a range of diseases. With a vision to revolutionize healthcare, the company focuses on innovative therapies that utilize light-based technology to address complex medical challenges. The Hemealumen Polychromatic Device At the core of Advanced Light Devices' portfolio is the Hemealumen Polychromatic Device, a state-of-the-art medical tool designed to combat both viral and bacterial diseases. In addition, this device is being used as a therapeutic option for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Applications in Infectious Disease Treatment The Hemealumen Polychromatic Device has demonstrated effectiveness in treating a variety of infectious diseases, including: Malaria Dengue fever COVID-19 Zika virus Shingles By utilizing targeted polychromatic light, the device disrupts the replication and survival mechanisms of pathogens, offering a non-invasive and innovative approach to disease management. Blood Treatment During Transfusions The Hemealumen Polychromatic Device is also used to treat blood during transfusions, effectively eliminating bacteria and viruses. This process enhances the safety of blood transfusions, reducing the risk of transfusion-transmitted infections and improving patient outcomes. Impact on Neurodegenerative Diseases Beyond infectious diseases, the device shows promise in the management of neurodegenerative conditions such as ALS and Parkinson's disease. Its mechanism of action may help reduce the progression of these disorders, though further research is ongoing to fully understand its therapeutic potential. Conclusion Advanced Light Devices, through the Hemealumen Polychromatic Device, is at the forefront of medical innovation. Their commitment to developing effective treatments for both infectious and neurodegenerative diseases position them as a leader in the field of light-based medical technology.

Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.

Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.

Biomeme is dedicated to advancing global health through innovative molecular detection technologies. Their mission is to provide rapid, reliable diagnostics that empower healthcare providers and researchers to make informed decisions in real-time, ultimately improving patient outcomes and public health responses. Biomeme emphasizes the importance of One Health, recognizing the interconnectedness of human, animal, and environmental health. They are at the forefront of combating antibiotic resistance through multifaceted approaches, including Host Response research, testing, and robust advocacy initiatives. Additionally, Biomeme fosters a culture of innovation and creativity, empowering its team to develop novel solutions for global health challenges.

BiosYnth s.r.l. is a biotechnology firm specializing in the research, development, and innovation of bacterial and viral vaccine platforms. With over 40 years of expertise, the company focuses on glycoconjugate, nanostructured vector, and synthetic peptide technologies to address invasive infectious diseases and antibiotic resistance. Operations comply with GLP and GMP standards and are supported by a robust patent portfolio and international collaborations.

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Caleo Biotechnologies develops patient-derived human translational models for preclinical therapeutic development. Our proprietary Organ-Dish™ platform generates multicellular 3D tissue models directly from human biospecimens while preserving key epithelial, stromal/mesenchymal, and immune compartments and features of native tissue biology. The platform enables evaluation of therapeutic efficacy, tissue injury and repair, inflammation, immune response, fibrosis and remodeling, and translational biomarkers in a patient-relevant human system. Organ-Dish™ models are scalable and compatible with pharmacologic, biologic, and cell-based therapeutic testing and downstream molecular and histologic analyses. Our approach aligns with the FDA’s increasing emphasis on human-relevant New Approach Methodologies (NAMs) to strengthen preclinical evidence and reduce reliance on animal testing. CaleoBio is interested in partnerships with therapeutic developers, biotechnology companies, academic investigators, and government/DoD teams seeking human translational models to support preclinical R&D and therapeutic development. Current and expanding applications include gastrointestinal disease, traumatic and complex wounds, pulmonary fibrosis, liver disease, and oncology.

ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.

CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.

Cooper University Health Care is a regional academic health system recognized for comprehensive clinical services, advanced multidisciplinary care, specialized surgery, and robust research in South Jersey. It provides integrated healthcare across general and specialty domains, including cancer, neurosciences, cardiology, trauma, genetics, addiction medicine, and complex surgical procedures, supported by leading technologies and a network of modern facilities.

CureLab Veterinary is a biotechnology company focused on the development of gene-based therapies targeting cancer and chronic inflammatory diseases in companion animals, such as dogs, cats, and horses. Utilizing advances in comparative medicine and translational immunology, the company applies a plasmid-based platform to stimulate anti-cancer immune responses, modulate tumor microenvironments, and mitigate chronic inflammation. Clinical research leverages academic partnerships and a robust intellectual property portfolio, pursuing efficient regulatory approval pathways in major markets, including the US and Europe. Recent studies suggest broader applications in pain management and cross-species translational potential.

Diadem Biotherapeutics is a biotechnology company focused on developing first- and best-in-class therapeutics by engineering extracellular vesicles to modulate immune responses. Their mission is to innovate beyond existing solutions to address unmet medical needs, leveraging expertise in immunology, bioengineering, and drug development. The company’s proprietary DECOSTAR™ platform enables precise costimulatory activation or repression of immune cells, targeting a range of diseases including cancer and autoimmunity.

Egret Therapeutics is a biotechnology company developing a novel therapy that targets the immune-mediated component of secondary neuronal damage to improve recovery after TBI. Our therapy has potential applications across combat injury (TBI, SCI, MSK, and polytrauma) and civilian markets (heart attack, stroke), where immune-mediated secondary damage leads to devastating outcomes.

Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment, utilizing Systems Biology and AI/ML. Evimero applies molecular principles to infectious disease and microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes and in people with infectious disorders. Evimero has an infectious disease product pipeline including both prophylactic and diagnostic assets against common causes of Travelers' Diarrhea, including a unique approach to preventing infection with human Norovirus, enterotoxigenic E. coli (ETEC) and others. Evimero's pipeline of drugs targeting human and animal microbiomes includes early-stage assets aimed at generalized microbiome-driven inflammation and gut leak, and specific disease-targeted disorders including Parkinson Disease and Inflammatory Bowel Diseases. Evimero's platform also makes possible a suite of point-of-care diagnostics that can be used for patient cohorting (infectious diseases), risk stratification, and ultimately informing therapeutic decision-making. The nature of Evimero's platform assures a steady stream of novel assets targeting both infectious diseases and chronic disorders with roots in microbiome dysfunction.

FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.

Florida Research & Innovation Center (FRIC) is a biomedical research organization specializing in infectious and inflammatory diseases, immunology, vaccine development, cancer biology, and organ transplantation immunology. The center emphasizes both basic and translational research, investigating mechanisms of disease, host-pathogen and host-tumor interactions, and sex-specific immune mechanisms. FRIC supports research with advanced core facilities in flow cytometry, imaging, and bioinformatics, and provides hands-on education and workforce development in biomedical research.

The GE HealthCare Technology & Innovation Center (HTIC) traces its roots to America's first industrial research facility, established by General Electric in 1900. Today, HTIC scientists tackle healthcare challenges through federal funding, academic collaboration, and private sector development. HTIC enhances GE HealthCare competitiveness through development of innovative technologies that enable creation of differentiated and disruptive products. HTIC engages in exploratory research in collaboration with clinicians and academia, guided by societal needs and governmental priorities to discover new markets. With operations in Niskayuna, NY, USA and Bangalore, India, HTIC translates federal research investments into clinical applications.